Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDOSTAR – Dostarlimab to prevent second primary cancers in cured cancer patients
2022-501316-34-00Phase 2Suspended
- Sponsor
- Centre Léon Bérard
- Start
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in cancer comparing Dostarlimab prophylaxis with Observation (2 arms). Primary endpoint: Incidence of second primary invasive cancer. Started Mar 2023; status: suspended.
02
Drugs
dostarlimab
03
Conditions
cancer
Beyond the preview
Go deeper on 2022-501316-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501316-34-00.